Dr. Kuerer on Challenges With Treating DCIS

Henry M. Kuerer, MD, PhD
Published: Thursday, Jun 30, 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

The biggest challenge with this disease is that patients with DCIS become fearful of their disease progressing, Kuerer explains. However, if patients are closely followed with proper imaging tools, it will be more likely that oncologists will be able to detect a progression of disease.

However, oncologists do not detect progression of disease in 20% of patients but with the use of ongoing clinical trials, Kuerer hopes that disease in these patients will not be clinically evident or that these patients will not need to be managed with endocrine therapy.
 
Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

The biggest challenge with this disease is that patients with DCIS become fearful of their disease progressing, Kuerer explains. However, if patients are closely followed with proper imaging tools, it will be more likely that oncologists will be able to detect a progression of disease.

However, oncologists do not detect progression of disease in 20% of patients but with the use of ongoing clinical trials, Kuerer hopes that disease in these patients will not be clinically evident or that these patients will not need to be managed with endocrine therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x